Vivace Therapeutics presented preclinical data showing VT-3989, a TEAD inhibitor, elicited tumor growth inhibition in in vitro and in vivo models of aggressive NF2-deficient meningioma. VT-3989 is in early clinical development for advanced solid tumors including refractory mesothelioma and the preclinical package supports further clinical evaluation. The data point to TEAD pathway blockade as a strategy for tumors driven by Hippo pathway dysregulation. Vivace will use these preclinical results to refine clinical cohorts and biomarker strategies for early-phase trials.